Crohn's Disease Market: By Procedures (Colonoscopy, Flexible Sigmoidoscopy, Computerized Tomography (CT), Magnetic Resonance Imaging (MRI), Capsule Endoscopy, Double-Balloon Endoscopy, Small Bowel Imaging), By Therapeutic Type (Non-surgical, Surgical), By End User (Hospitals and Clinics, Research Institutes, Diagnostic Centres and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online and Others), and Geography 

Crohn’s Disease Market valued at USD 10,923.4 million in 2023 and is expected to grow at 6.4% CAGR over the forecast years 2024 – 2030. Crohn's Disease is characterized by inflammation in the gastrointestinal tract, causing symptoms such as abdominal pain, diarrhea, weight loss, and fatigue. According to report findings 2021, the prevalence of Crohn's Disease has been on the rise worldwide, affecting approximately 3.2 per 1,000 individuals in the United States and around 322 per 100,000 individuals in Europe. In Europe, the incidence of Crohn's Disease varies among countries, with the highest reported rates in Northern Europe. Furthermore, the European healthcare system faces substantial economic consequences due to this disease, with estimates indicating that direct medical costs surpass 5,000 per patient per year.

In recent years, the Crohn's Disease market has witnessed a surge in research and development activities, leading to the emergence of targeted biologic therapies. These therapies, such as anti-TNF agents and integrin receptor antagonists, have shown promising results in inducing and maintaining remission, improving patients' quality of life. Moreover, ongoing research explores the potential of novel treatments, including JAK inhibitors and stem cell therapies, indicating a promising future for patients with Crohn's Disease. Additionally, advancements in telemedicine and digital health technologies have facilitated better remote patient monitoring and disease management, empowering individuals to access healthcare services more conveniently. The integration of artificial intelligence and data analytics in managing Crohn's Disease has shown potential in predicting disease flares and optimizing treatment strategies for improved patient outcomes.

Crohn’s Disease Market Key Developments:

• In June 2022, AbbVie Inc., a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved SKYRIZI (Risankizumab) as the first and only specific interleukin-23 (IL-23) inhibitor for the treatment of adults with moderately to severely active Crohn's disease (CD).
• In March 2022, Tiziana Life Sciences, a biotechnology company, commenced a Phase Ib clinical trial of oral enteric-coated capsules of Foralumab (TZLS-401), a monoclonal antibody (mAb), in mild-to-moderate Crohn’s disease (CD) patients.